

# Osteoarthritis and Cartilage



## Recommendations for standardization and phenotype definitions in genetic studies of osteoarthritis: the TREAT-OA consortium

H.J.M. Kerkhof ††\*, I. Meulenbelt ‡§, T. Akune ||, N.K. Arden ¶#, A. Aromaa ††, S.M.A. Bierma-Zeinstra ††, A. Carr #, C. Cooper ¶#, J. Dai §§, M. Doherty ||||, S.A. Doherty ||||, D. Felson ¶¶, A. Gonzalez ##, A. Gordon †††††, A. Harilainen §§§, D.J. Hart |||||, V.B. Hauksson ¶¶¶, M. Heliövaara ††, A. Hofman †###, S. Ikegawa †††, T. Ingvarsson †††, Q. Jiang §§, H. Jonsson §§§§§, I. Jonsdottir ¶¶¶§§§§, H. Kawaguchi |||||, M. Kloppenburg ¶¶¶¶, U.M. Kujala #####, N.E. Lane ††††, P. Leino-Arjas ††††, L.S. Lohmander §§§§§, F.P. Luyten |||||, K.N. Malizos ¶¶¶¶¶, M. Nakajima †††, M.C. Nevitt ††††, H.A.P. Pols †, F. Rivadeneira ††###, D. Shi §§, E. Slagboom ‡§, T.D. Spector ||||, K. Stefansson ¶¶¶§§§§, A. Sudo #####, A. Tamm †††††, A.E. Tamm †††††, A. Tsezou §§§§§§, A. Uchida #####, A.G. Uitterlinden ††###, J.M. Wilkinson ††††, N. Yoshimura |||||, A.M. Valdes ||||, J.B.J. van Meurs ††

† Department of Internal Medicine, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands

‡ The Netherlands Genomics Initiative-sponsored Netherlands Consortium for Healthy Aging (NGI-NCHA), Rotterdam/Leiden, the Netherlands

§ Department of Molecular Epidemiology, Leiden University Medical Center, Leiden, the Netherlands

|| Department of Clinical Motor System Medicine, 22nd Century Medical and Research Center, The University of Tokyo, Tokyo, Japan

¶ MRC Epidemiology Resource Centre, University of Southampton, Southampton General Hospital, Southampton, United Kingdom

# NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford England Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences University of Oxford, Oxford, United Kingdom

†† The National Institute for Health and Welfare (THL), Helsinki, Finland

‡‡ Department of General Practice, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands

§§ Center of Diagnosis and Treatment for Joint Disease, Nanjing Drum Tower Hospital, The affiliated Hospital of Nanjing University Medical School, Nanjing, China

||| Academic Rheumatology, Clinical Sciences Building, Nottingham City Hospital Hucknall Road, Nottingham, United Kingdom

¶¶ Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, United States

## Laboratorio Investigacion and Rheumatology Unit, Hospital Clinico Universitario Santiago, Santiago de Compostela, Spain

††† Academic Unit of Bone Metabolism, Department of Human Metabolism, University of Sheffield, Sheffield, United Kingdom

†††† Sheffield NIHR Bone Biomedical Research Unit, Centre for Biomedical Research, Northern General Hospital, Sheffield, United Kingdom

§§§ ORTON Orthopedic Hospital, Invalid Foundation, Helsinki, Finland

|||| Department of Twin Research and Genetic Epidemiology, St. Thomas' Hospital, King's College London, London, United Kingdom

¶¶¶ deCODE Genetics, Reykjavik, Iceland

### Department of Epidemiology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands

†††† Laboratory for Bone and Joint Diseases, Center for Genomic Medicine, RIKEN, Japan

††††† FSA University Hospital, Institution of Health Science, University of Akureyri, Akureyri, Iceland

§§§§ Department of Medicine, Landspítali University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland

||||| Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan

¶¶¶¶ Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands

##### Department of Health Sciences, University of Jyväskylä, Jyväskylä, Finland

††††† University of California at San Francisco and University of California at Davis, Sacramento, United States

†††††† Finnish Institute of Occupational Health, Helsinki, Finland

§§§§§ Department of Orthopedics, Clinical Sciences, Lund University, Lund, Sweden

||||||| Laboratory for Skeletal Development and Joint Disorders, Division of Rheumatology, Katholieke Universiteit Leuven, Belgium

¶¶¶¶¶ Department of Orthopaedics, Faculty of Medicine, University of Thessaly, Larissa, Greece

##### Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Japan

†††††† Department of Internal Medicine, University of Tartu, Estonia

††††††† Department of Sport Medicine and Rehabilitation, University of Tartu, Estonia

§§§§§§ Department of Biology, Faculty of Medicine, University of Thessaly, Larissa, Greece

||||||| Department of Joint Disease Research, 22nd Century Medical and Research Center, The University of Tokyo Hospital, The University of Tokyo, Tokyo, Japan

\* Address correspondence and reprint requests to: Hanneke J.M. Kerkhof, Genetic Laboratory Department of Internal Medicine, Room Ee2183, Erasmus MC, MC PO Box 1738, 3000 DR Rotterdam, the Netherlands, Tel: 31-107044292.

E-mail address: j.m.kerkhof@erasmusmc.nl (H.J.M. Kerkhof).

## ARTICLE INFO

## Article history:

Received 7 June 2010

Accepted 26 October 2010

## Keywords:

Genetics  
Osteoarthritis  
Phenotype  
Definition  
TREATOA

## SUMMARY

**Objective:** To address the need for standardization of osteoarthritis (OA) phenotypes by examining the effect of heterogeneity among symptomatic (SOA) and radiographic osteoarthritis (ROA) phenotypes.

**Methods:** Descriptions of OA phenotypes of the 28 studies involved in the TREAT-OA consortium were collected. We investigated whether different OA definitions result in different association results by creating various hip OA definitions in one large population based cohort (the Rotterdam Study I (RSI)) and testing those for association with gender, age and body mass index using one-way ANOVA. For ROA, we standardized the hip-, knee- and hand ROA definitions and calculated prevalence's of ROA before and after standardization in nine cohort studies. This procedure could only be performed in cohort studies and standardization of SOA definitions was not feasible at this moment.

**Results:** In this consortium, all studies with SOA phenotypes (knee, hip and hand) used a different definition and/or assessment of OA status. For knee-, hip- and hand ROA five, four and seven different definitions were used, respectively. Different hip ROA definitions do lead to different association results. For example, we showed in the RSI that hip OA defined as "at least definite joint space narrowing (JSN) and one definite osteophyte" was not associated with gender ( $P = 0.22$ ), but defined as "at least one definite osteophyte" was significantly associated with gender ( $P = 3 \times 10^{-9}$ ). Therefore, a standardization process was undertaken for ROA definitions. Before standardization a wide range of ROA prevalence's was observed in the nine cohorts studied. After standardization the range in prevalence of knee- and hip ROA was small.

**Conclusion:** Phenotype definitions influence the prevalence of OA and association with clinical variables. ROA phenotypes within the TREAT-OA consortium were standardized to reduce heterogeneity and improve power in future genetics studies.

© 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.

## Introduction

The Translational Research in Europe Applied Technologies for OsteoArthritis (TREAT-OA) consortium was established in January 2008 to address the generalisability and utility of genetic and biochemical risk factors ([www.treatoa.eu](http://www.treatoa.eu)). The two main goals of TREAT-OA are (1) to develop efficient diagnostics for risk and progression of osteoarthritis (OA) and (2) to identify new targets for therapeutic interventions. This will be done by identification of genes and biochemical markers consistently associated with risk and progression of OA, but also by defining the roles of these genes in molecular pathways involved in disease aetiology, for example by the development of *in vivo* transgenic animal OA model systems.

A major goal of the consortium is to identify new genes consistently associated with risk and progression of OA. To reach this goal, large-scale genome-wide association studies (GWASs) and meta-analyses are being performed. To date, research within the TREAT-OA consortium has resulted in the identification of a novel genetic locus on chromosome 7q22 that is associated with knee- and hand OA<sup>1</sup>, which was confirmed by a recently published GWAS meta-analysis on knee OA<sup>2</sup>. In addition, the ataxin 2 binding protein 1 gene<sup>3</sup> and the prostaglandin-endoperoxide synthase 2 gene<sup>4</sup> have been found associated with respectively hand- and knee OA.

One of the difficulties in these genetic analyses, and also in general in epidemiological research of OA is heterogeneity of the definition of the phenotype under study. Heterogeneity of the definition of the phenotype among different studies reduces power to find consistent associations in any disease<sup>5</sup>. Two working groups of Human Genome Epidemiology Network (HuGENet) and National Cancer Institute – National Human Genome Research Institute (NCI-NHGRI) have published recommendations for replication studies in genetic epidemiology studies<sup>6–8</sup>. One of their recommendations was to try to investigate the same or a very similar phenotype in replication studies. Specifically for OA, the American College of Rheumatology (ACR) criteria were developed to define clinical OA within a secondary care setting<sup>9</sup> and the OARSI-OMERACT initiative proposed definitions for radiological progression of hip- and knee OA<sup>10</sup>. The problem of heterogeneity in genetic association studies of OA has been highlighted<sup>11</sup> and therefore standardized radiographic OA (ROA)

phenotypes were used in our recent GWAS and subsequent meta-analysis<sup>1</sup>. However, symptomatic OA (SOA) and ROA phenotypes were both used within the same meta-analysis. For ROA, several grading systems exist, but the most widely and consistently used system is the Kellgren and Lawrence (K/L) grading system<sup>12</sup>. Among major cohort studies, K/L scores are interpreted differently, especially for the knee and hip, despite the fact that they all refer to the original description<sup>13–15</sup>.

In the current study, we have examined the effect of heterogeneity among SOA and ROA phenotypes on association analyses, to address the need for standardization of OA phenotypes to enhance power for future association studies. We further provide recommendations for standardization of OA phenotypes.

## Subjects and methods

## Study populations

We collected data for 28 studies currently involved in the TREAT-OA consortium on the following nine items: (1) reference article, (2) study design, (3) ethnic origin, (4) country of origin, (5) joint site(s) studied, (6) ROA or SOA definition, (7) availability of age and/or body mass index (BMI) data, (8) percentage of women in the study and (9) availability of follow-up data. Table I describes the characteristics of all studies evaluated. A short description of each study is given in the [Supplementary data](#).

## OA definitions

OA phenotypes can be categorized into SOA and ROA, and this information was collected from all studies. Subsequently, we asked for the exact OA definition used in that particular study. For example, if a study used a K/L score and used the cut-off value defined by a summary grade of 2 or more to define OA cases, the exact description of a K/L of 2 was requested (e.g., definite osteophytes with possible joint space narrowing (JSN) vs definite osteophyte(s) only) or a reference article was asked where the exact interpretation of the K/L score was given.

**Table 1**  
Overview of all studies involved in the TREAT-OA consortium

Study	Reference article	Study design	Ethnic origin	Country of origin	Joint site	ROA/SOA	Age/BMI	% Women	Follow-up data
<i>GWAS data</i>									
arcOGEN consortium		Case–control	Caucasian	United Kingdom	Knee, hip	ROA/SOA	–	60%	Not available
Chingford Study	Hart and Spector <sup>36</sup>	Cohort	Caucasian	United Kingdom	Knee, hip	SOA	+	100%	Available
Nottingham Case–Control Study	Valdes <i>et al.</i> <sup>37</sup>	Case–control	Caucasian	United Kingdom	Knee, hip	SOA	+	53%	Not available
Oxford Study	Chapman <i>et al.</i> <sup>38</sup>	Case–control	Caucasian	United Kingdom	Knee, hip	SOA	–	55%	Not available
Sheffield Study	Gordon <i>et al.</i> <sup>39</sup>	Case–control	Caucasian	United Kingdom	Hip	SOA	+*	53%	Not available
TwinsUK	Spector and Williams <sup>40</sup>	Cohort	Caucasian	United Kingdom	Knee, hip	ROA	+	100%	Available
VIDEO	Not available yet	RCT	Caucasian	United Kingdom	Knee	SOA	+	60%	Available in 2011
<i>Other</i>									
deCODE	Ingvarsson <sup>41</sup> and Stefansson <i>et al.</i> <sup>42</sup>	Case–control	Caucasian	Iceland	Knee, hip, hand	SOA	+*	58%	Not available
Framingham Osteoarthritis Study	Hunter <i>et al.</i> <sup>43</sup>	Cohort	Caucasian	United States	Knee, hand	ROA	+	56%	Available
GARP	Riyazi <i>et al.</i> <sup>44</sup>	Cohort	Caucasian	Netherlands	Knee, hip, hand	SOA/ROA	+	65%	Available
Health 2000	Kaila-Kangas <sup>45</sup>	Cohort	Caucasian	Finland	Hip, knee	SOA	+	55%	Available
RSI	Hofman <i>et al.</i> <sup>46</sup>	Cohort	Caucasian	Netherlands	Knee, hip, hand	ROA	+	59%	Available
RSII	Hofman <i>et al.</i> <sup>46</sup>	Cohort	Caucasian	Netherlands	Knee, hip, hand	ROA	+	56%	Available
RSIII	Hofman <i>et al.</i> <sup>46</sup>	Cohort	Caucasian	Netherlands	Knee, hip, hand	ROA	+	57%	Available in future
TwinsUK	Spector and Williams <sup>40</sup>	Cohort	Caucasian	United Kingdom	Knee, hip, hand	ROA	+	100%	Available
<i>De novo genotyping</i>									
Chingford Study	Hart and Spector <sup>36</sup>	Cohort	Caucasian	United Kingdom	Knee, hip, hand	ROA	+	100%	Available
Chinese Case–Control Study	Miyamoto <i>et al.</i> <sup>47</sup>	Case–control	Asian	China	Knee	SOA	+†	75%	Not available
D&T Study	Solovieva <i>et al.</i> <sup>48</sup>	High risk cohort	Caucasian	Finland	Hand	ROA	+	100%	Only symptoms
Estonian Studies	Tamm <i>et al.</i> <sup>49</sup>	Cohort	Caucasian	Estonia	Knee	ROA	+	65%	Available
Finnish OA cases	Näkki <i>et al.</i> <sup>50</sup>	Case–control	Caucasian	Finland	Hand, knee	SOA/ROA	+	76%	Not available
Greek clinical cases	Fytilli <i>et al.</i> <sup>51</sup>	Case–control	Caucasian	Greece	Knee	SOA	+	78%	Not available
HCS	Abdin-Mohamed <i>et al.</i> <sup>17</sup>	Cohort	Caucasian	United Kingdom	Knee, hand	ROA	+	50%	Available‡
Japanese Case–Control Study	Miyamoto <i>et al.</i> <sup>47</sup>	Case–control	Asian	Japan	Knee, hip	SOA	+†	80%	Not available
Japanese Cohort Study	Miyamoto <i>et al.</i> <sup>47</sup>	Cohort	Asian	Japan	Knee	ROA	+	75%	Available§
KANON	Frobell <i>et al.</i> <sup>52</sup>	High risk cohort	Caucasian	Sweden	Knee	ROA	+	26%	Available in 2011
LUMEN	Englund and Lohmander <sup>18</sup>	High risk cohort	Caucasian	Sweden	Knee	ROA	+	21%	Available
MDC study	Lohmander <i>et al.</i> <sup>53</sup>	Cohort	Caucasian	Sweden	Knee, hip	SOA	+	65%	Available
MrOS	Orwoll <i>et al.</i> <sup>54</sup>	Cohort	Caucasian	United States	Hip	ROA	+	0%	Available
Nottingham Case–Control	Valdes <i>et al.</i> <sup>37</sup>	Case–control	Caucasian	United Kingdom	Knee, hip	SOA	+	53%	Not available
Spanish clinical cases	Rodriguez-Lopez <i>et al.</i> <sup>55</sup>	Case–control	Caucasian	Spain	Knee, hip, hand	SOA	+	65%	Not available
SOF	Nevitt <i>et al.</i> <sup>56</sup>	Cohort	Caucasian	United States	Hip	ROA	+	100%	Available
The ROAD Study	Muraki <i>et al.</i> <sup>57</sup>	Cohort	Asian	Japan	Knee	ROA	+	65%	Available in 2010

GWAS = genome-wide association study; ROA = radiographic osteoarthritis; SOA = symptomatic osteoarthritis; BMI = body mass index; RCT = randomized clinical trial; GARP = Genetics osteoARthritis and Progression; RS = Rotterdam Study; D&T = dentists & teachers; HCS = Hertfordshire cohort study; MDC = Malmö Diet and Cancer; MrOS = Osteoporotic Fractures in Men Study; ROAD = Research on Osteoarthritis/Osteoporosis Disability; SOF = Study of Osteoporotic Fractures; Age/BMI +: age and BMI data are available for all subjects; D&T = dentists & teachers; MDC = Malmö Diet and Cancer.

\* Age is available for all subjects, BMI only for part of the subjects.

† Only for the cases data on age and BMI is available.

‡ Available for clinical data, not available for X-ray data.

§ For part of the subjects follow-up data is available.

#### Data analysis of OA phenotypes within the Rotterdam Study I (RSI)

Within RSI radiographic features are scored separately for hip OA (such as osteophytes, sclerosis and JSN at the lateral, superior

and axial site of the hip joint)<sup>16</sup>. In addition, total hip replacement (THR) and the presence of pain during the last month are recorded. To discover if differences in case definitions result in different association results, we created all hip OA case definitions used by

**Table IIa**

Description of the radiographic knee OA definition according to 14 studies of the TREAT-OA consortium

Study	Classification system	Cut-off value for OA	Exact OA definition
Chingford Study	K/L score	2	One definite osteophyte
Estonian Studies	K/L score	2	Definite osteophytes
Finnish cases	K/L score	3	Definite osteophytes + definite JSN and/or joint deformation
Framingham Osteoarthritis Study	K/L score	2	Definite osteophytes and possible JSN
GARP	K/L score	2	Definite osteophytes and possible JSN
HCS	K/L score	2	Definite osteophytes
Japanese Cohort Study	K/L score	2	One definite osteophyte
KANON	–	–	JSN grade $\geq 2$ or sum of two marginal osteophyte grades from the same compartment $\geq 2$ or grade 1 JSN + grade 1 osteophytes in the same compartment
LUMEN	–	–	JSN grade $\geq 2$ or sum of two marginal osteophyte grades from the same compartment $\geq 2$ or grade 1 JSN + grade 1 osteophytes in the same compartment
RSI	K/L score	2	Definite osteophytes and possible JSN
RSII	K/L score	2	Definite osteophytes and possible JSN
RSIII	K/L score	2	Definite osteophytes and possible JSN
The ROAD Study	K/L score	2	One definite osteophyte
TwinsUK	K/L score	2	One definite osteophyte

K/L = Kellgren/Lawrence; JSN = joint space narrowing; GARP = Genetics osteoARthritis and Progression; RS = Rotterdam Study; HCS = Hertfordshire cohort study; ROAD = Research on Osteoarthritis/Osteoporosis Disability; – No standard classification system is used to define OA.

studies of the consortium within RSI. Association analyses were performed to study the relationship between different OA definitions of the hip and age, gender and BMI. One-way ANOVA was used to assess the relationship between hip OA and the clinical variables. The analyses were carried out using SPSS version 15.0.

#### Standardization of phenotypes

Consensus on which ROA phenotype to use within the TREAT-OA consortium was based on the ROA definition as originally described by K/L and the feasibility of its use within each of the studies<sup>12</sup>. Total joint replacements (TJR) due to primary OA visible on radiographs are considered as OA. TJR due to fractures and other diseases were excluded as much as possible. After a consensus was reached between consortium members, the cohort studies either shared their data with our research group (RS) who standardized the definitions (data of TwinsUK, Chingford Study) or performed the standardization process themselves (other studies) if they were able and willing to standardize their ROA definition. The prevalence of OA was calculated by dividing the number of prevalent ROA cases over controls. Before standardization, controls were defined as the absence of OA, according to the definition used by each study, at the joint site

studied. After standardization, controls were defined as the absence of OA, according to the standardized definition as described in the results section, at the joint site studied.

## Results

#### Study populations

Since the start of the TREAT-OA consortium in 2008, the number of teams collaborating with the consortium has grown to include 28 teams participating as of April 2010. The studies originate from Europe, the United States of America and Asia. In 24 of the 28 studies (86%), the majority of subjects included are women (63% on average). With respect to genetic data, there are in total 11 studies with GWAS data, two studies in which part of the subjects have GWAS data and 15 studies without GWAS data. A short description of all studies involved in the consortium is given in the [Supplementary data](#).

#### OA definitions

In total, there were 11 studies using a symptomatic definition of OA and 15 studies with a radiographic definition. Two studies could not be classified as completely SOA/ROA.

**Table IIb**

Description of the radiographic hand OA definition according to nine studies of the TREAT-OA consortium

Study	Classification system	Cut-off value for OA	Exact OA definition
Chingford Study	K/L score	2	$\geq 3$ Joints (DIP/PIP/CMC1) affected*
D&T Study	Modified K/L score	2	$\geq 2$ Joints (DIP/PIP/MCP) affected†
Finnish OA cases and families	K/L score	2–3	K/L $\geq 3$ for index cases and K/L $\geq 2$ for their siblings (DIP bilateral)
Framingham Osteoarthritis Study	K/L score	2	K/L $\geq 2$ (one definite osteophyte): joint specific definitions (i.e., DIP OA, PIP OA etcetera)
GARP	K/L score	2	$\geq 3$ Joints (DIP/PIP/CMC1) affected‡
HCS	–	–	Presence of Heberden's or Bouchard's nodes
LUMEN	–	–	Presence of OA (JSN grade $\geq 2$ or osteophyte grade $\geq 2$ or JSN grade 1 + osteophyte grade 1) in at least one DIP or PIP joint in each hand symmetrically or at least one DIP/PIP joints in the same hand in a pattern consistent with primary OA (in the same row or ray) or the CMC1 joint bilaterally
RSI	K/L score	2	Two out of three hand joint groups (DIP/PIP/CMC1 or TS) affected*
TwinsUK	K/L score	2	$\geq 3$ Joints (DIP/PIP/CMC1) affected*

K/L = Kellgren/Lawrence; DIP = distal interphalangeal joint; PIP = proximal interphalangeal joint; CMC1 = first carpometacarpal joint; TS = trapezioscapoid joint; MCP = metacarpophalangeal joint; GARP = Genetics osteoARthritis and Progression; RS = Rotterdam Study; D&T = dentists & teachers; HCS = Hertfordshire cohort study – No standard classification system is used to define OA.

\* Affected means K/L  $\geq 2$  (=definite osteophyte) in each or both hands.

† Affected means modified K/L  $\geq 2$  (=a single radiographic sign indicative of OA, slight to moderate lowering of the joint space, sometimes subluxation, minimal osteophytes, degeneration cysts or slight marginal sclerosis, each of the latter signs without a clear narrowing of joint space but little if any additional pathology) irrespective of right or left hand.

‡ Affected means K/L  $\geq 2$  (=definite osteophyte) irrespective of left or right hand.

**Table IIc**  
Description of the radiographic hip OA definition according to seven studies of the TREAT-OA consortium

Study	Classification system	Cut-off value for OA	Exact OA definition
Chingford Study	K/L score	2	Definite osteophyte
GARP Study	K/L score	2	Definite JSN + definite osteophyte
MrOS	Modified Croft grade	2	Presence of either definite JSN or definite osteophytes plus at least one of five other features: osteophytes, JSN, sclerosis, cysts or femoral head deformity
RSI	K/L score	2	Definite JSN + definite osteophyte
RSII	K/L score	2	Definite JSN + definite osteophyte
SOF	Modified Croft grade	2	Presence of either definite JSN or definite osteophytes plus at least one of five other features: osteophytes, JSN, sclerosis, cysts or femoral head deformity
TwinsUK	Croft grade	1	Definite osteophytes

OA = osteoarthritis; K/L = Kellgren and Lawrence; JSN = joint space narrowing; GARP = Genetics osteoARthritis and Progression; MrOS = Osteoporotic Fractures in Men Study; RSI = Rotterdam Study-I; RSII = Rotterdam study-II; RSIII = Rotterdam Study-III; SOF = Study of Osteoporotic Fractures.

### ROA

For knee OA, there are 14 studies using radiographic definitions of knee OA shown in Table IIa with a detailed description of the knee ROA definition. A total of 12 studies used the K/L score, of which 11 studies used a cut-off value of 2 to define knee ROA and one study used a more stringent cut-off of 3. Two studies, which are both high risk cohorts, used a definition of OA not according to a standard classification system. As is shown in Table IIa, four different interpretations are given for the K/L score of the knee considering a cut-off value of 2 although all studies used the original K/L atlas. In Tables IIb and c, results are given for hand- and hip ROA respectively in a similar way as for knee ROA.

For hand ROA, most studies (seven out of nine) used the K/L score to define hand OA, with the exception of two studies<sup>16,17</sup>.

The interpretation of this K/L score is the same for all these studies, but there are four different hand ROA definitions based on the number of joints included. For example, two studies define OA in one hand joint as at least one definite osteophyte, but hand OA is defined as “≥3 joints (distal interphalangeal joint (DIP)/proximal interphalangeal joint (PIP)/first carpometacarpal joint (CMC1)) affected” in one study and “2 out of 3 hand joint groups (DIP/PIP/CMC1 or trapezioscapoid joint (TS)) affected” in another study.

Hip ROA was defined by the (modified) Croft grade in three studies and by the K/L score in four studies. Also for hip ROA there is no consensus on the interpretation of the K/L score as two different interpretations are present among the studies. This includes both “definite JSN and a definite osteophyte” OR “one definite osteophyte”. The Croft grade cut-off of 1 as a criterion for hip ROA, is defined as definite osteophytes and does not include JSN.

### SOA

For knee OA, there are 10 studies using clinical definitions of knee OA, which are shown in Table IIIa. In total, four of these 10 studies defined knee OA as ROA + symptoms, but the inclusion of patients was done in four different ways. For example, one study used a K/L score ≥ 2 (defined as one definite osteophyte) + medial joint space > 1 mm + pain to include patients, whilst another study used a K/L score ≥ 3 + SOA and treated on a regular basis. The other six studies included patients on the basis of TJRs due to primary OA or a combination of a TJR or ROA and clinical symptoms of OA.

In Tables IIIb and c, results are given for hand ( $n = 2$ ) and hip ( $n = 8$ ) SOA respectively in a similar way as for SOA of the knee. Also, these definitions differed for each study. In summary, hand SOA was defined by either ACR criteria or by patient records. Hip SOA was defined as a THR by three studies although the assessment was different for all three studies (i.e., based on hospital records vs based on the description of a rheumatologist). In addition, two studies defined SOA of the hip as symptoms of OA + ROA, but the definition of ROA is unclear and inclusion based on symptoms differs. Furthermore, there were three additional studies defining hip SOA again in another way (i.e., incident THR or either clinical records of SOA or a THR).

**Table IIIa**  
Description of the symptomatic knee OA definitions according to 10 studies of the TREAT-OA consortium

Study	OA definition based on	Exact OA definition
Chinese Case–Control Study	K/L grade + symptoms	K/L ≥ 2 (=one definite osteophyte) + pain with rest and/or night pain of over 5-month duration. Exclusion of inflammatory, posttraumatic, post septic arthritis, dysplasias
deCODE	Hospital records of TJR	TKR. A clinician reviewed the patients records to verify the diagnosis
Greek clinical cases	TJR due to OA reported by specialist	TKR + K/L ≥ 2 (=definite osteophytes + possible JSN)
Health 2000	Clinical records of OA or TKR	History, records and a standardized clinical diagnosis of previously diagnosed knee OA or knee arthroplasty due to OA based on convincing findings OR at least moderately restricted mobility OR slightly restricted mobility and either of the following: documented history of previously diagnosed knee OA but not convincingly presented grounds for the diagnosis or typical symptoms of knee OA
Japanese Case–Control Study	K/L grade + symptoms	SOA and treated on a regular basis + K/L ≥ 3
MDC Study	Incident knee arthroplasty/osteotomy from national Swedish hospital discharge register	First knee arthroplasty or high tibial osteotomy + diagnosis of OA according to the International Classification of Disease (ICD) 9 and 10
Nottingham Case–Control	Clinically severe knee OA based on hospital orthopaedic surgery lists	Referred to the hospital with symptomatic, clinically severe knee OA and the majority had undergone unilateral or bilateral TKR within the previous 5 years. Pre-operative knee radiographs were examined to confirm the diagnosis. Exclusion based on another major arthropathy, Paget's disease
Oxford Study	Severe symptomatic knee OA + K/L grade	Signs and symptoms of OA sufficiently severe to require TKR + K/L ≥ 2 (exact definition unknown). Exclusion based on dysplasia
Spanish clinical cases	TJR	TKR, a rheumatologists considered patients to suffer from severe primary OA. Exclusion based on inflammatory, infectious, traumatic or congenital joint pathology and lesions due to crystal deposition or osteonecrosis
VIDEO	K/L grade + pain	K/L ≥ 2 (=one definite osteophyte) + medial joint space width > 1 mm + knee pain

OA = osteoarthritis; TJR = total joint replacement; TKR = total knee replacement; JSN = joint space narrowing; MDC = Malmö Diet and Cancer.

**Table IIIb**

Description of the symptomatic hand OA definitions according to two studies of the TREAT-OA consortium

Study	OA definition based on	Exact OA definition
deCODE	Patients records at hospitals and health centres	Included on the basis of clinical examination by an experienced examiner, supported by a radiograph for >60% of the cases
Spanish clinical cases	ACR criteria	Patients were complaining of hand OA and followed in the Rheumatology Unit. The ACR criteria were used for inclusion in the study

OA = osteoarthritis; ACR = American College of Rheumatology.

*Data analysis of OA phenotypes within the RSI*

In Table IV, association results are given for the relationship between age, gender and BMI and different hip OA definitions. When hip OA was defined radiographically as “one definite osteophyte” subjects with hip OA were more frequently men compared to controls (mean difference of 10%,  $P = 3 \times 10^{-9}$ ), whilst subjects with a THR were more frequently women compared to controls (mean difference of 21%,  $P = 0.001$ ). When ROA definitions were compared, we observed that hip ROA defined as “one definite osteophyte” were more frequently men compared to controls ( $P = 3 \times 10^{-9}$ ), whilst hip OA defined as “definite JSN and one definite osteophyte” was not associated with gender ( $P = 0.22$ ). When analyzing SOA, we did not observe clear differences in association results for the different definitions of SOA, but the number of cases for SOA is much lower than for ROA, therefore results should be taken with caution.

*Standardization of phenotypes*

Consensus was reached for the knee- and hip OA definition based on the ROA definition as originally described by K/L<sup>12</sup> and at the feasibility within each of the studies. It was agreed that the knee ROA definition used within the TREAT-OA consortium is the original K/L score<sup>12</sup> defined as “definite osteophytes and possible JSN” at the tibio-femoral (TF) joint. If studies did not score possible JSN as

a separate feature, the definition used was: “at least two definite osteophytes OR one definite osteophyte plus definite JSN”. Hip ROA, which was the most poorly specified in the original scores, was defined as “at least definite JSN”. For hand ROA, consensus was not reached within the consortium, due to the fact that different studies graded different joints for hand OA, thus limiting the possibility to generate a single definition. As an alternative, thumb OA was put forward as an interesting phenotype to study, because of the high correlation with pain and disability<sup>19</sup>. Consensus was reached on a definition for thumb OA which is “at least one definite osteophyte (=original K/L grade  $\geq 2$ ) in either the left or right CMC1”.

In Table V, the number of cases and controls for each study are given after standardization of phenotypes (both SOA and ROA). In total, there are 13,119 knee OA cases and 61,538 controls, 9521 hip OA cases and 59,345 controls and 4913 hand OA cases and 41,863 controls with DNA and phenotype data within the TREAT-OA consortium.

To evaluate the effect of standardization of the ROA phenotypes, we calculated the prevalence of knee- and hip ROA in eight Caucasian and one Japanese cohort study before and after standardization of the ROA definition. In Table VI, the mean age and BMI are shown for the nine cohorts. The Framingham Osteoarthritis Study, The Hertfordshire Cohort Study (HCS), The Osteoporotic Fractures in Men Study (MrOS), The RSI, the ROAD Study and the Study of Osteoporotic Fractures (SOF) are on average 14 years older than The Chingford Study, the RSI and TwinsUK. The result of the standardization of knee- and hip OA phenotypes is shown in Fig. 1. Results for the thumb OA phenotype are not shown since all studies use the same definition. The standardized hip OA definition is “at least definite JSN or a THR visible on the radiograph due to primary OA”. In the SOF and MrOS Study a minor adjustment was made and hip ROA was defined as: “at least medial JSN (grade  $\geq 3$ ) or lateral JSN (grade  $\geq 2$ ) or a THR visible on the radiograph due to primary OA”. The standardized knee ROA definition is “at least definite osteophytes and possible JSN or a total knee replacement (TKR) visible on the radiograph due to primary OA”.

Before standardization the prevalence of knee OA ranged between 10% and 55%, of hip OA between 2% and 33%. After standardization the prevalence of knee OA ranged from 8% to 25% and

**Table IIIc**

Description of the symptomatic hip OA definitions according to eight studies of the TREAT-OA consortium

Study	OA definition based on	Exact OA definition
deCODE	Hospital records of TJR	THR. A clinician reviewed the patients records to verify the diagnosis History, records and a standardized clinical diagnosis of previously diagnosed hip OA or hip arthroplasty due to OA based on convincing findings OR at least moderate restrictions in extension or in inner rotation or in outer rotation OR slight restrictions in extension, inner rotation, outer rotation or at least moderately restricted abduction-adduction and either of the following: documented history of previously diagnosed hip OA but no grounds for the diagnosis is given or typical symptoms of hip OA Subjects are symptomatic and were treated in participating institutions on a regular basis + radiographic signs of hip OA (exact definition unknown)
Health 2000	Clinical records of OA or THR	
Japanese Case–Control Study	Symptoms + radiographs	First hip arthroplasty in combination with a contemporaneous diagnosis of hip OA according to the International Classification of Disease (ICD) 9 and 10
MDC Study	Incident hip arthroplasty from national Swedish hospital discharge register	
Nottingham Case–Control	Clinically severe hip OA based on hospital orthopaedic surgery lists	Referred to the hospital with symptomatic, clinically severe hip OA and the majority had undergone unilateral or bilateral THR within the previous 5 years. Pre-operative hip radiographs were examined to confirm the diagnosis. Exclusion based on another major arthropathy, Paget's disease, overt child hip disease, THR due to trauma or terminal illness
Oxford Study	Severe symptomatic hip OA + K/L grade	
Sheffield Study	THR	Signs and symptoms of OA sufficiently severe to require THR + K/L $\geq 2$ (exact definition unknown). Exclusion based on dysplasia
Spanish clinical cases	TJR	
		Subjects had undergone THR for clinical, idiopathic OA that was confirmed radiographically prior to joint replacement (exact radiographic definition unknown) THR, a rheumatologists considered patients to suffer from severe primary OA. Exclusion based on inflammatory, infectious, traumatic or congenital joint pathology and lesions due to crystal deposition or osteonecrosis

OA = osteoarthritis; TJR = total joint replacement; THR = total hip replacement; MDC = Malmö Diet and Cancer.

**Table IV**  
Association results of different hip OA case definitions (prevalence) and gender, age and BMI in the RSI

OA phenotype	Number		Gender (% women)			Age (mean)			BMI (mean)		
	Cases	Controls	Cases	Controls	P-value	Cases	Controls	P-value	Cases	Controls	P-value
<b>ROA</b>											
Definite JSN and one definite osteophyte (original K/L $\geq 2$ )	242	3037	54%	58%	0.22	68.1	65.7	$3 \times 10^{-8}$	26.3	26.3	0.99
One definite osteophyte	1906	1373	54%	64%	$3 \times 10^{-9}$	66.1	65.5	0.009	26.2	26.4	0.07
<b>SOA</b>											
THR	64	3215	78%	57%	0.001	71.2	65.7	$8 \times 10^{-11}$	26.9	26.3	0.18
ROA (original K/L $\geq 2$ ) + pain	58	3221	79%	57%	0.001	69.9	65.8	$3 \times 10^{-6}$	26.7	26.3	0.38
ROA (original K/L $\geq 3$ ) + pain	23	3256	70%	58%	0.26	70.0	65.8	0.003	26.4	26.3	0.88

hip OA between 4% and 10%. When comparing cohorts with the same age range, the prevalence of knee ROA was 8–12% in the younger cohorts and 16–25% in the cohorts with subjects of an older age. To show that the differences in age are indeed the cause of the

**Table V**  
Number of cases (including incident cases) and controls in each study involved in the TREAT-OA consortium according to standardized phenotypes

Study	Knee OA		Hip OA		Thumb OA	
	Cases	Controls	Cases	Controls	Cases	Controls
<b>ROA</b>						
Chingford Study	80	560	34	702	356	620
D&T Study	–	–	–	–	36	507
Estonian Studies	70	441	–	–	–	–
Framingham Osteoarthritis Study	419	1674	–	–	913	2783
HCS	156	831	–	–	78	179
Japanese Cohort Study	226*	486	–	–	–	–
KANON	NA*	NA	–	–	–	–
LUMEN	152*	317	–	–	55	197
MrOS	–	–	389	3660	–	–
RSI	1017†	2452	581†	3183	868‡	2516
RSII	NA†	NA	NA†	NA	NA†	NA
RSIII	136	922	NA†	NA	–	–
SOF	–	–	364	3668	–	–
The ROAD Study	541	2,426	–	–	–	–
TwinsUK	149	1436	105	1253	393	1565
<b>Subtotal ROA</b>	<b>2946</b>	<b>11,545</b>	<b>1473</b>	<b>12,466</b>	<b>2699</b>	<b>8364</b>
<b>SOA/ROA</b>						
Finnish OA cases	113	210	–	–	–§	–§
GARP	161	720	106	720	151	720
<b>Subtotal SOA/ROA</b>	<b>274</b>	<b>930</b>	<b>106</b>	<b>720</b>	<b>151</b>	<b>720</b>
<b>SOA</b>						
Arcogen consortium	4287	4287	4107	4107	–	–
Chinese Case–Control Study	1200	1500	200	1500	–	–
deCODE	1033	32,482	1571	32,482	1822	32,482
Greek clinical cases	228	344	67	344	–	–
Health 2000	237	6048	132	6151	–	–
Japanese Case–Control Study	900	3400	–	–	–	–
MDC	471	471	551	551	–	–
Nottingham Case–Control	1355	237	1011	730	–	–
Spanish clinical cases	188	294	303	294	241¶	294
<b>Subtotal SOA</b>	<b>9899</b>	<b>49,063</b>	<b>7942</b>	<b>46,159</b>	<b>2063</b>	<b>32,776</b>
<b>Total</b>	<b>13,119</b>	<b>61,538</b>	<b>9521</b>	<b>59,345</b>	<b>4913</b>	<b>41,863</b>

NA = not applicable.

\* Number of cases and controls unstandardized.

† Complete dataset available summer 2010.

‡ Scoring of radiographs in progress, complete dataset available in 2011.

§ Available in the near future.

|| Recruitment in progress.

¶ Hand OA according to ACR criteria, thumb OA definition not possible.

lower prevalence of knee OA in three cohort studies, we studied the prevalence of knee ROA in one relatively young and one old cohort with a wide age range, respectively TwinsUK and RSI. The prevalence of knee ROA ranged from 10% to 15% in subjects aged 65 years and younger. In subjects aged 65 years and older, the prevalence ranged from 29% to 34% for the two studies.

## Discussion

A wide range of OA definitions were used in the 28 studies participating in the TREAT-OA consortium. Since heterogeneity in phenotype definitions will reduce power to find consistent associations, ROA phenotypes were standardized within the consortium.

There are some research fields in which specific attention is given to phenotype definitions. This mainly concerns studies in the field of neuroscience (i.e., bipolar disorder or schizophrenia)<sup>20</sup> and obesity<sup>21</sup>. In contrast, published research involving OA, osteoporosis and heart disease does not usually discuss phenotype definitions. Our results showed that OA definitions should be standardized since association results differ when varying ROA and SOA definitions are used within the same study. In addition, it was recently shown that the ability to detect hip OA genetic associations is influenced by proper phenotyping<sup>22</sup>. We showed by standardizing of ROA phenotypes, that similar ROA prevalence's could be obtained.

For hip ROA, a distinction can be made between atrophic OA (presence of JSN without osteophytes), hypertrophic OA (presence of osteophytes without JSN) or a composite score (both JSN and osteophytes)<sup>23</sup>. It is known that these different forms of hip ROA have different risk factors<sup>24,25</sup>. In addition, atrophic OA shows to be a more progressive form of OA than hypertrophic OA<sup>26</sup>. Since some studies interpret a K/L score  $\geq 2$  as one definite osteophyte, whereas other studies interpret this as definite JSN and one definite osteophyte, a difference in association results would be expected. Although the standardized definition agreed upon by the consortium is based on JSN (hip ROA = at least definite JSN, with or without osteophytes), a majority of the subjects (78% and 80% in the RSI and RSIII, respectively) have both JSN and osteophytes. This definition can therefore also be seen as a composite score. Although less often used than the composite score of hip ROA, hypertrophic hip and atrophic hip ROA definitions should also be standardized. We suggest using “presence of at least one definite osteophyte at the femoral head without definite JSN” as preferred definition for hypertrophic OA and “definite JSN without the presence of any osteophytes at all locations” as atrophic OA which was also used in a previous study by Javaid *et al.*<sup>23</sup>.

It was difficult to reach consensus on the hand ROA definition, since different studies scored different joints. To overcome this problem, a subtype for clinically relevant OA was suggested within the consortium: thumb OA, associated with pain and disability<sup>19,27</sup>, will be used within the consortium. The definition of ROA of the

**Table VI**

Baseline characteristics of six cohort studies with ROA phenotypes involved in the standardization process

Study	Mean age (range)	Mean BMI (range)
Chingford Study	54 (44–67)	26 (17–47)
Framingham Osteoarthritis Study	64 (29–93)	26 (14–54)
HCS	65 (59–71)	27 (17–48)
Osteoporotic Fracture in Men Study	77 (69–97)	27 (18–50)
ROAD Study	70 (23–94)	23 (13–37)
RSI	68 (55–94)	26 (15–59)
RSIII	57 (45–89)	28 (14–57)
SOF	71 (65–91)	27 (16–59)
TwinsUK	54 (37–76)	25 (15–51)

thumb is “at least one definite osteophyte in either right or left CMC1 joint”.

We recommend for future studies on ROA to always specify the exact OA definition. A statement such as “we defined OA as a K/L  $\geq 2$ ” should be avoided or the interpretation of this K/L score should be given.


Since all studies involved in the consortium defined SOA differently, or at least assessed the OA status differently, it is likely that heterogeneity is a problem in studies on SOA. Standardization of SOA would in principle be possible if studies had pain, clinical assessment data for study subjects, as well as radiographic grade for the index joints, age, BMI, for both cases and controls. The design of some studies is such however that there is no radiographic characterization for cases and controls, which is necessary if SOA would be defined based on both symptoms and radiographs, and only a diagnosis of TJR for an indication of OA is present. These are extant studies and to collect homogenous SOA studies would require a huge investment of resources as well as time. However, there remains a lack of consensus and guidelines about how SOA should be assessed. For example, the ACR defines signs of OA as stiffness  $< 30$  min, crepitus, bony tenderness, bony enlargement, no palpable warmth and pain in or around the joint. The presence of these traits in subjects over the age of 50 (preferably accompanied by radiographic evidence of OA) is

commonly used in the design of randomized clinical trials (RCTs)<sup>28</sup>. But these criteria were developed in a clinic setting so the sensitivity and specificity of a diagnosis based on these criteria in a community or primary care settings, are as yet unknown.

Most of the SOA cases included in the TREAT-OA consortium are TJR cases with a primary indication of OA. Although it is possible to define TJR as the main clinical outcome representative of severe symptomatic large joint OA in itself, as has been proposed for RCTs<sup>29</sup>, this might not be the best option. Recent studies on this topic have revealed considerable heterogeneity in the radiographic severity, functional disability and pain suffered by TJR candidates<sup>30</sup>. In addition, the pain and disability components among subjects undergoing TJR are significantly correlated with risk factors that also impact on ROA such as BMI, age, sex, whilst being poorly correlated with radiographic severity<sup>30,31</sup>. Further, not all patients with severe SOA can or are willing to get a TJR either because of lack of access to healthcare, or they may be afraid of surgery, or have co-morbidities that make them ineligible etcetera<sup>32</sup>. TJR patients are usually recruited in secondary care settings and might in some instances represent a non-random subset of severe SOA.

In summary, additional research is needed to reach consensus for in- and exclusion criteria and definitions of clinical OA/SOA studies. We suggest that more thought should be given to the establishment of clear guidelines for future research using SOA cohorts, as this would have implications not just for genetic studies, but also for the assessment of biomarkers, imaging and interventional studies.

GWASs and meta-analyses have been<sup>1,33</sup> and will continue to be performed within the TREAT-OA consortium in order to identify genes consistently associated with risk and progression of OA. Presently, there are few genes discovered for OA by means of GWAS, and this may be explained by heterogeneity of phenotypes and the limited sample size used in the discovery GWAS samples up to now. For example, in a previous GWAS, ROA and SOA definitions were used within one meta-analysis<sup>1</sup>. It has been shown before that ROA



**Fig. 1.** Prevalence of knee- and hip OA before and after standardization of the ROA phenotypes.

shows only modest correlation with clinical features of OA<sup>34,35</sup>. In addition, we showed in this study that the association between SOA and age, gender and BMI is different compared to ROA. Although the sample size would decrease using stratification methods, the statistical power might increase if there is a reduction in the heterogeneity in the phenotype definition. Therefore, we recommend that for future GWASs additional work is needed to standardize or stratify on ROA and SOA.

Fortunately, in the TREAT-OA consortium studies on ROA have access to the source material and individual features of ROA are scored separately. This enables us to easily establish standardized phenotypes across cohorts.

Additionally, other phenotypes or possible predictors such as hypertrophic vs atrophic forms of OA, joint shape, Magnetic Resonance Imaging (MRI) based features, severe ROA ( $K/L \geq 3$  vs  $K/L = 0$ ) or generalized OA may expand our definitions of the OA phenotypes and may increase the number of consistent associations in genetic studies. However, consensus among OA epidemiologist on OA phenotypes should be reached within the OA field, prior to the performance of these association studies.

In conclusion, standardization of ROA phenotypes was carried out in the TREAT-OA consortium to reduce heterogeneity as much as possible. Standardization of SOA phenotypes, although desirable, was not possible due to the case–control study design of the studies. In the future, more precise OA phenotypes and stratification according to SOA and ROA phenotypes are highly recommended.

#### Recommendations

- 1 Future studies on OA should always **specify the exact OA definition**. A statement such as “we defined OA as a  $K/L \geq 2$ ” should be avoided or the interpretation of this K/L score should be given.
- 2 **The use of standardized ROA definitions is recommended** in association studies with knee ROA defined as “at least two moderate definite osteophytes and possible JSN at the TF joint”, hip ROA as “at least definite JSN” and thumb ROA as “at least one moderate definite osteophyte at the CMC1 joint”.
- 3 **Atrophic hip ROA** is suggested to be defined as “definite JSN without the presence of any osteophytes at all locations” and **hypertrophic hip ROA** as “presence of at least one moderate definite osteophyte at the femoral head without definite JSN”.
- 4 **Consensus is needed** on in- and exclusion criteria and phenotype definitions of **SOA studies**. More thought should be given to the establishment of clear guidelines for future research using clinical OA cohorts.
- 5 For future **GWASs** additional work must be done to **stratify** on age/BMI and especially **ROA and SOA**.
- 6 **Expansion of OA phenotypes is not discouraged**. Other phenotypes such as joint shape, MRI based features, severe ROA ( $K/L \geq 3$  vs  $K/L = 0$ ) or generalized SOA/ROA may expand our definitions of the OA phenotypes, but consensus among OA epidemiologist on these new OA phenotypes should be reached, prior to the performance of these association studies.

#### Author contribution

*Responsible for the integrity of the work as a whole:* JBJ van Meurs and HJM Kerkhof.

*Conception and design:* HJM Kerkhof, TD Spector, AM Valdes, JBJ van Meurs, AG Uitterlinden, I Meulenbelt.

*Analysis and interpretation of data:* HJM Kerkhof, NE Lane, NK Arden, I Meulenbelt, N Yoshimura, A Tamm, MC Nevitt, UM Kujala, P Leino-Arjas, D Felson, FP Luyten, AM Valdes, JBJ van Meurs, M Kloppenburg, F Rivadeneira, S Lohmander, TD Spector.

*Drafting of the article:* HJM Kerkhof, AM Valdes, JBJ van Meurs.

*Critical revision of the article:* all authors.

*Final approval of the article:* all authors.

*Provision of study material or patients:* I Meulenbelt, NK Arden, A Aromaa, A Carr, C Cooper, J Dai, M Doherty, SA Doherty, D Felson, A Gonzalez, DJ Hart, M Heliovaara, A Hofman, S Ikegawa, T Ingvarsson, Q Jiang, H Jonsson, I Jonsdottir, UM Kujala, NE Lane, P Leino-Arjas, S Lohmander, MC Nevitt, E Slagboom, TD Spector, K Stefansson, A Tamm, A Tsezou, JM Wilkinson, JBJ van Meurs, AG Uitterlinden, AM Valdes, N Yoshimura.

*Obtaining of funding:* I Meulenbelt, E Slagboom, NK Arden, A Aromaa, A Carr, C Cooper, M Doherty, D Felson, A Gonzalez, A Hofman, S Ikegawa, Q Jiang, M Kloppenburg, UM Kujala, NE Lane, P Leino-Arjas, S Lohmander, MC Nevitt, HAP Pols, TD Spector, K Stefansson, A Tamm, A Tsezou, AG Uitterlinden, JM Wilkinson, N Yoshimura, AM Valdes, JBJ van Meurs.

*Collection of data:* T Akune, J Dai, A Gordon, A Harilainen, VB Hauksson, H Kawaguchi, M Kloppenburg, M Nakajima, D Shi, A Sudo, AE Tamm, A Uchida, I Meulenbelt, NK Arden, A Aromaa, A Carr, C Cooper, J Dai, M Doherty, SA Doherty, D Felson, A Gonzalez, DJ Hart, M Heliovaara, A Hofman, S Ikegawa, T Ingvarsson, Q Jiang, H Jonsson, I Jonsdottir, UM Kujala, NE Lane, P Leino-Arjas, S Lohmander, MC Nevitt, E Slagboom, TD Spector, K Stefansson, A Tamm, A Tsezou, JM Wilkinson, JBJ van Meurs, AG Uitterlinden, AM Valdes, N Yoshimura, HJM Kerkhof, JM Wilkinson.

#### Conflict of interest

None declared.

#### Acknowledgments

This study is funded by the European Commission framework 7 programme TREAT-OA (grant 200800). The RS is supported by the Netherlands Organisation of Scientific Research NWO Investments (no. 175.010.2005.011, 911-03-012), the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) (project no. 050-060-810) Netherlands Consortium of Healthy Aging and the Erasmus Medical Center and Erasmus University, Rotterdam. The deCODE study is funded by deCODE Genetics. The Academy of Finland, Finnish Ministry of Education and ORTON Research Institute, Invalid Foundation has supported the studies on Finnish OA cases and families. The Framingham Osteoarthritis Study is funded by the National Institutes of Health AR47785 and AG18393. The Oxford Study is supported by the Oxford NIHR Musculoskeletal Biomedical Research Unit. TwinsUK acknowledges financial support from the Wellcome Trust, the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and Arthritis Research Campaign. The Chingford Study is funded by the arc. The HCS is funded by the Medical Research Council (UK) and the Oxford NIHR Musculoskeletal Biomedical Research Unit. The Arthritis Research Council UK funded collection of some of the Nottingham OA study cases (grant 17661) and provided infrastructure support during the Nottingham OA study (grant 14581). The Estonian collection is funded by the Estonian Science Foundation grant no. 5308, the Estonian Ministry of Social Affairs grants no. 9.6-4/2035 and 12.1-5/597. The Swedish cohort studies were supported by the Swedish Research Council and Lund University. The Genetics osteoArthritis and Progression (GARP) Study was supported by the Leiden University Medical Centre and the Dutch Arthritis Association. Pfizer Inc., Groton, CT, USA supported the inclusion of the GARP study.

The MrOS is supported by National Institutes of Health funding. The following institutes provide support: the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on Aging (NIA), the National Center for Research

Resources (NCRR), and NIH Roadmap for Medical Research under the following grant numbers: U01 AR45580, U01 AR45614, U01 AR45632, U01 AR45647, U01 AR45654, U01 AR45583, U01 AG18197, U01-AG027810, R01 AR052000-01 A1, 2K24-AR04884, AR043052 and UL1 RRO24140. DNA extraction for MrOS was supported by grant number R01-AR051124 from The National Institute of Arthritis and Musculoskeletal Diseases (NIAMS). The SOF is supported by National Institutes of Health funding. The National Institute on Aging (NIA) provides support under the following grant numbers: AG05407, AR35582, AG05394, AR35584, AR35583, R01 AG005407, R01 AG027576-22, 2 R01 AG005394-22A1, R01 AR052000-01 A1, 2K24-AR04884, AR043052 and 2 R01 AG027574-22A1.

The authors are very grateful to all study participants, the staff from all studies and the participating physicians and pharmacists.

### Supplementary data

Supplementary data related to this article can be found online at doi:10.1016/j.joca.2010.10.027.

### References

- Kerkhof HJ, Lories RJ, Meulenbelt I, Jonsdottir I, Valdes AM, Arp P, et al. A genome-wide association study identifies an osteoarthritis susceptibility locus on chromosome 7q22. *Arthritis Rheum* 2010;62:499–510.
- Evangelou E, Valdes AM, Kerkhof HJ, Styrkarsdottir U, Zhu Y, Meulenbelt I, et al. Meta-analysis of genome-wide association studies confirms a susceptibility locus for knee osteoarthritis on chromosome 7q22. *Ann Rheum Dis* 2010 Nov 10 [epub ahead of print]
- Zhai G, van Meurs JB, Livshits G, Meulenbelt I, Valdes AM, Soranzo N, et al. A genome-wide association study suggests that a locus within the ataxin 2 binding protein 1 gene is associated with hand osteoarthritis: the Treat-OA consortium. *J Med Genet* 2009;46:614–6.
- Valdes AM, Loughlin J, Timms KM, van Meurs JJ, Southam L, Wilson SG, et al. Genome-wide association scan identifies a prostaglandin-endoperoxide synthase 2 variant involved in risk of knee osteoarthritis. *Am J Hum Genet* 2008;82:1231–40.
- Moonesinghe R, Khoury MJ, Liu T, Ioannidis JP. Required sample size and nonreplicability thresholds for heterogeneous genetic associations. *Proc Natl Acad Sci U S A* 2008;105:617–22.
- Ioannidis JP, Boffetta P, Little J, O'Brien TR, Uitterlinden AG, Vineis P, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. *Int J Epidemiol* 2008;37:120–32.
- Ioannidis JP, Gwinn M, Little J, Higgins JP, Bernstein JL, Boffetta P, et al. A road map for efficient and reliable human genome epidemiology. *Nat Genet* 2006;38:3–5.
- Studies N-NWGoRIA, Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, et al. Replicating genotype–phenotype associations. *Nature* 2007;447:655–60.
- Altman RD. Criteria for the classification of osteoarthritis of the knee and hip. *Scand J Rheumatol Suppl* 1987;65:31–9.
- Ornetti P, Brandt K, Helliö-Le Graverand MP, Hochberg M, Hunter DJ, Kloppenburg M, et al. OARSI-OMERACT definition of relevant radiological progression in hip/knee osteoarthritis. *Osteoarthritis Cartilage* 2009;17:856–63.
- Kerkhof JM, Uitterlinden AG, Valdes AM, Hart DJ, Rivadeneira F, Jhamai M, et al. Radiographic osteoarthritis at three joint sites and FRZB, LRP5, and LRP6 polymorphisms in two population-based cohorts. *Osteoarthritis Cartilage* 2008;16(10):1141–9.
- Kellgren JH, Lawrence JS. Radiological assessment of osteoarthritis. *Ann Rheum Dis* 1957;16:494–502.
- Schipfoph D, Boers M, Bierma-Zeinstra SM. Differences in descriptions of Kellgren and Lawrence grades of knee osteoarthritis. *Ann Rheum Dis* 2008;67:1034–6.
- Altman RD, Hochberg M, Murphy Jr WA, Wolfe F, Lequesne M. Atlas of individual radiographic features in osteoarthritis. *Osteoarthritis Cartilage* 1995;3(Suppl A):3–70.
- Hart DJ, Spector TD. The classification and assessment of osteoarthritis. *Bailliere Clin Rheumatol* 1995;9:407–32.
- Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. *Arthritis Rheum* 2004;50:2471–8.
- Abdin-Mohamed M, Jameson K, Dennison EM, Cooper C, Arden NK, Hertfordshire Cohort Study G. Volumetric bone mineral density of the tibia is not increased in subjects with radiographic knee osteoarthritis. *Osteoarthritis Cartilage* 2009;17:174–7.
- Englund M, Lohmander LS. Risk factors for symptomatic knee osteoarthritis fifteen to twenty-two years after meniscectomy. *Arthritis Rheum* 2004;50:2811–9.
- Bijsterbosch J, Visser W, Kroon HM, Stamm T, Meulenbelt I, Huizinga TW, et al. Thumb base involvement in symptomatic hand osteoarthritis is associated with more pain and functional disability. *Ann Rheum Dis* 2010;69:585–7.
- Sabb FW, Burggren AC, Higier RG, Fox J, He J, Parker DS, et al. Challenges in phenotype definition in the whole-genome era: multivariate models of memory and intelligence. *Neuroscience* 2009;164:88–107.
- Kring SI, Larsen LH, Holst C, Toubro S, Hansen T, Astrup A, et al. Genotype–phenotype associations in obesity dependent on definition of the obesity phenotype. *Obes Facts* 2008;1(3):138–45.
- Valdes AM, Mc Williams D, Arden NK, Doherty SA, Wheeler M, Muir KR, et al. Different risk factors are involved in clinically severe large joint osteoarthritis according to the presence of hand interphalangeal nodes. *Arthritis Rheum* 2010;62(9):2688–95.
- Javaid MK, Lane NE, Mackey DC, Lui LY, Arden NK, Beck TJ, et al. Changes in proximal femoral mineral geometry precede the onset of radiographic hip osteoarthritis: the study of osteoporotic fractures. *Arthritis Rheum* 2009;60:2028–36.
- Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. *Ann Intern Med* 2000;133:635–46.
- Lane NE, Gore LR, Cummings SR, Hochberg MC, Scott JC, Williams EN, et al. Serum vitamin D levels and incident changes of radiographic hip osteoarthritis: a longitudinal study. Study of Osteoporotic Fractures Research Group. *Arthritis Rheum* 1999;42:854–60.
- Lieverse AM, Bierma-Zeinstra SM, Verhagen AP, Verhaar JA, Koes BW. Prognostic factors of progress of hip osteoarthritis: a systematic review. *Arthritis Rheum* 2002;47:556–62.
- Dahaghin S, Bierma-Zeinstra SM, Ginai AZ, Pols HA, Hazes JM, Koes BW. Prevalence and pattern of radiographic hand osteoarthritis and association with pain and disability (the Rotterdam study). *Ann Rheum Dis* 2005;64:682–7.
- Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the

- American Rheumatism Association. *Arthritis Rheum* 1986;29:1039–49.
29. Altman RD, Abadie E, Avouac B, Bouvenot G, Branco J, Bruyere O, et al. Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. *Osteoarthritis Cartilage* 2005;13:13–9.
  30. Dieppe P, Judge A, Williams S, Ikwueke I, Guenther KP, Floeren M, et al. Variations in the pre-operative status of patients coming to primary hip replacement for osteoarthritis in European orthopaedic centres. *BMC Musculoskelet Disord* 2009;10:19.
  31. Bedson J, Croft PR. The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature. *BMC Musculoskelet Disord* 2008;9:116.
  32. Ballantyne PJ, Gignac MA, Hawker GA. A patient-centered perspective on surgery avoidance for hip or knee arthritis: lessons for the future. *Arthritis Rheum* 2007;57:27–34.
  33. Evangelou E, Chapman K, Meulenbelt I, Karassa FB, Loughlin J, Carr A, et al. Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand. *Arthritis Rheum* 2009;60:1710–21.
  34. Peat G, Thomas E, Duncan R, Wood L, Hay E, Croft P. Clinical classification criteria for knee osteoarthritis: performance in the general population and primary care. *Ann Rheum Dis* 2006;65:1363–7.
  35. Creamer P, Hochberg MC. Why does osteoarthritis of the knee hurt – sometimes? *Br J Rheumatol* 1997;36:726–8.
  36. Hart DJ, Spector TD. Cigarette smoking and risk of osteoarthritis in women in the general population: the Chingford study. *Ann Rheum Dis* 1993;52:93–6.
  37. Valdes AM, Arden NK, Tamm A, Kisand K, Doherty S, Pola E, et al. A meta-analysis of interleukin-6 promoter polymorphisms on risk of hip and knee osteoarthritis. *Osteoarthritis Cartilage* 2010;18:699–704.
  38. Chapman K, Takahashi A, Meulenbelt I, Watson C, Rodriguez-Lopez J, Egli R, et al. A meta-analysis of European and Asian cohorts reveals a global role of a functional SNP in the 5' UTR of GDF5 with osteoarthritis susceptibility. *Hum Mol Genet* 2008;17:1497–504.
  39. Gordon A, Kiss-Toth E, Stockley I, Eastell R, Wilkinson JM. Polymorphisms in the interleukin-1 receptor antagonist and interleukin-6 genes affect risk of osteolysis in patients with total hip arthroplasty. *Arthritis Rheum* 2008;58:3157–65.
  40. Spector TD, Williams FM. The UK Adult Twin Registry (TwinsUK). *Twin Res Hum Genet* 2006;9:899–906.
  41. Ingvarsson T. Prevalence and inheritance of hip osteoarthritis in Iceland. *Acta Orthop Scand Suppl* 2000;298:1–46.
  42. Stefansson SE, Jonsson H, Ingvarsson T, Manolescu I, Jonsson HH, Olafsdottir G, et al. Genomewide scan for hand osteoarthritis: a novel mutation in matrilin-3. *Am J Hum Genet* 2003;72:1448–59.
  43. Hunter DJ, Demissie S, Cupples LA, Aliabadi P, Felson DT. A genome scan for joint-specific hand osteoarthritis susceptibility: the Framingham study. *Arthritis Rheum* 2004;50:2489–96.
  44. Riyazi N, Meulenbelt I, Kroon HM, Runday KH, Hellio le Graverand MP, Rosendaal FR, et al. Evidence for familial aggregation of hand, hip, and spine but not knee osteoarthritis in siblings with multiple joint involvement: the GARP study. *Ann Rheum Dis* 2005;64:438–43.
  45. Kaila-Kangas E. Musculoskeletal Disorders and Diseases in Finland. Results of the Health 2000 Survey. National Public Health Institute, Finland, Finnish Institute of Occupational Health, University of Kuopio, Finland Publications of the National Public Health Institute B25/2007; Helsinki, 2007.
  46. Hofman A, Breteler MM, van Duijn CM, Janssen HL, Krestin GP, Kuipers EJ, et al. The Rotterdam study: 2010 objectives and design update. *Eur J Epidemiol* 2009;24:553–72.
  47. Miyamoto Y, Mabuchi A, Shi D, Kubo T, Takatori Y, Saito S, et al. A functional polymorphism in the 5' UTR of GDF5 is associated with susceptibility to osteoarthritis. *Nat Genet* 2007;39:529–33.
  48. Solovieva S, Vehmas T, Riihimaki H, Luoma K, Leino-Arjas P. Hand use and patterns of joint involvement in osteoarthritis. A comparison of female dentists and teachers. *Rheumatology (Oxford)* 2005;44:521–8.
  49. Tamm A, Lintrop M, Veske K, Hansen U, Tamm A. Prevalence of patello- and tibiofemoral osteoarthritis in Elva, Southern Estonia. *J Rheumatol* 2008;35:543–4.
  50. Nakki A, Kouhia ST, Saarela J, Harilainen A, Tallroth K, Videman T, et al. Allelic variants of IL1R1 gene associate with severe hand osteoarthritis. *BMC Med Genet* 2010;11:50.
  51. Fyttili P, Giannatou E, Papanikolaou V, Stripeli F, Karachalios T, Malizos K, et al. Association of repeat polymorphisms in the estrogen receptors alpha, beta, and androgen receptor genes with knee osteoarthritis. *Clin Genet* 2005;68:268–77.
  52. Frobell RB, Lohmander LS, Roos EM. The challenge of recruiting patients with anterior cruciate ligament injury of the knee into a randomized clinical trial comparing surgical and non-surgical treatment. *Contemp Clin Trials* 2007;28:295–302.
  53. Lohmander LS, Gerhardsson de Verdier M, Roloff J, Nilsson PM, Engstrom G. Incidence of severe knee and hip osteoarthritis in relation to different measures of body mass: a population-based prospective cohort study. *Ann Rheum Dis* 2009;68:490–6.
  54. Orwoll E, Blank JB, Barrett-Connor E, Cauley J, Cummings S, Ensrud K, et al. Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study – a large observational study of the determinants of fracture in older men. *Contemp Clin Trials* 2005;26:569–85.
  55. Rodriguez-Lopez J, Pombo-Suarez M, Liz M, Gomez-Reino JJ, Gonzalez A. Lack of association of a variable number of aspartic acid residues in the asporin gene with osteoarthritis susceptibility: case-control studies in Spanish Caucasians. *Arthritis Res Ther* 2006;8(3):R55.
  56. Nevitt MC, Lane NE, Scott JC, Hochberg MC, Pressman AR, Genant HK, et al. Radiographic osteoarthritis of the hip and bone mineral density. The Study of Osteoporotic Fractures Research Group. *Arthritis Rheum* 1995;38:907–16.
  57. Muraki S, Oka H, Akune T, Mabuchi A, En-yo Y, Yoshida M, et al. Prevalence of radiographic knee osteoarthritis and its association with knee pain in the elderly of Japanese population-based cohorts: the ROAD study. *Osteoarthritis Cartilage* 2009;17:1137–43.